礼来推迟申报减重药retatrutide
2026-07-23 10:51:22
据CNBC报道，礼来（Eli Lilly）表示，将在2027年第一季度申请其下一代肥胖症药物retatrutide的批准。该公司此前曾称，最早可能在今年提交这款每周注射药的申请；如今表示，需要更多时间收集并核实监管机构要求的生产和质量控制数据。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
Mobileye创始人将卸任CEONext article：
礼来下一代减重针再过关
